TCT 2016: Stents, stents, stents on Day 1

Micell’s MiStent’s 5-year results

Micell Technologies posted 5-year results from the Dessolve I and II trials of its MiStent sirolimus-eluting bioresorbable-polymer stent, showing a combined target lesion revascularization rate of 2.7% with no probable or definite stent thromboses.

“These results from Dessolve I and II validate our initial hypothesis that MiStent’s unique pharmacokinetic profile, with a rapidly absorbing polymer and extended elution of crystalline sirolimus, permits faster and stable vessel healing that translates to exceptional long-term outcomes,” Dr. David Kandzari, of Atlanta’s Piedmont Heart Institute, said in prepared remarks.

“This pooled analysis of patients treated with MiStent, which has a linear drug release and ultra-thin-strut, cobalt chromium stent design, suggests excellent long term safety and efficacy of this novel coronary stent,” added Dr. Dean Kereiakes of Cincinnati’s Christ Hospital Heart & Vascular Center.

“MiStent uniquely provides continued vascular drug delivery for nine months – even after its bioresorbable polymer coating has been fully absorbed, which occurs over the course of 90 days,” according to Micell’s chief medical advisor Dr. Dennis Donohoe. “Studies of MiStent to date have demonstrated a desirable lack of late lumen loss over 18 months, a characteristic that makes MiStent a clinically meaningful improvement in treating patients with coronary artery disease.”

Building Better Companies at DeviceTalks Minnesota DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as: Navigating the path to market Reimbursement Winning regulatory approval Corporate culture Entering global markets Leadership Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code SAVE15 to save 15%! REGISTER NOW